IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunocore : JPMorgan Starts Immunocore Holdings at Overweight With $58 Price Target

03/02/2021 | 08:06am EDT


© MT Newswires 2021
All news about IMMUNOCORE HOLDINGS PLC
05/23Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and E..
PR
05/23Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and E..
AQ
05/11Immunocore Holdings Q1 Net Loss Narrows as Revenue Rises
MT
05/11Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/11Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
GL
04/18IMMUNOCORE : Corporate Presentation - April 2022
PU
04/07Immunocore to present at the 21st Annual Needham Healthcare Conference
AQ
04/04IMMUNOCORE : European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unr..
PU
04/04Immunocore Wins European Regulatory Ok of Kimmtrak for Unresectable or Metastatic Uveal..
MT
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2022 83,5 M 105 M 105 M
Net income 2022 -89,2 M -112 M -112 M
Net cash 2022 226 M 285 M 285 M
P/E ratio 2022 -11,1x
Yield 2022 -
Capitalization 958 M 1 205 M 1 205 M
EV / Sales 2022 8,76x
EV / Sales 2023 9,99x
Nbr of Employees 324
Free-Float 37,6%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2 181,64 GBX
Average target price 4 291,74 GBX
Spread / Average Target 96,7%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
John Irving Bell Chairman
David Berman Head-Research & Development
Travis Coy Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC-16.15%1 260
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232